Lexaria Bioscience Corp. LEXX
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a cardio-renal-metabolic drug developer. Its lead program, DehydraTECH-GLP-1 (GLP-1-H24-4), is in Phase 1 for Obesity/GLP-1 oral delivery. Its next catalyst on record is GLP-1-A26-1/A26-2: Animal study results (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GLP-1-A26-1/A26-2 — Animal study results (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| DehydraTECH-semaglutide (GLP-1-H24-4) | Obesity/weight | small molecule | Phase 1 |
| DehydraTECH-CBD | Hypertension | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.